Dear Editor, we would like to discuss on “Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5–11 years: Results from an active pharmacovigilance study in central Italy.Citation1 ” Through active surveillance reporting, Ripabelli et al. evaluated the adverse reactions following vaccination with the mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine in children aged 5 to 11 in central Italy.Citation1 According to Ripabelli et al., only 5.7% and 3.9% of children reported adverse effects to doctors, and 17.6% and 15.8% of those children received treatment.Citation1 The safety profile of mRNA BNT162b2 among children in Italy was initially reported by Ripabelli et al., who found that each dose of the vaccine was followed by brief, mild-to-moderate symptoms and no significant adverse effects.Citation1
The surveillance data may provide important information about the vaccine’s safety. However, in each indexed instance with a clinical concern following immunization, it should talk about the procedure of verifying the precise underlying reason. It is important to take into account any hazards associated with the COVID-19 vaccination because co-morbidity can be difficult to manage.Citation2 For instance, a person who received the COVID-19 vaccine may also have dengue.Citation2 If a clinical issue develops after the immunization, this usually isn’t a good alternative. Prior to receiving a vaccine, it is essential to rule out any underlying illnesses or co-morbidities to prevent any clinical issues. Dengue can also contribute to hyposmia and transient audiovestibular.Citation3 Another problem that needs to be taken into account is asymptomatic COVID-19. A previous asymptomatic COVID-19 cannot be ruled out by a basic history. Patients with SARS-Co-V2 may not be identified because they show no symptoms. Contrary to other illnesses, co-morbidity is occasionally thought to have adverse effects.Citation4 Recent studies Citation5 have also connected recipient immunological responses to the COVID-19 with underlying genetic variance. Future studies should consider the diverse genetic background.
Disclosure statement
No potential conflict of interest was reported by the author(s).
Data availability statement
Data sharing is not applicable to this article as no new data were created or analyzed in this study.
Additional information
Funding
References
- Ripabelli G, Sammarco ML, D’Amico A, De Dona R, Iafigliola M, Parente A, Samprati N, Santagata A, Adesso C, Natale A, et al. Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: results from an active pharmacovigilance study in central Italy. Hum Vaccin Immunother. 2022 Oct 31;2126668. Online ahead of print. doi:10.1080/21645515.2022.2126668.
- Kebayoon A, Wiwanitkit V. Dengue after COVID-19 vaccination: possible and might be missed. Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211047229. doi:10.1177/10760296211047229.
- Hilmy AI, Dey RK, Imad HA, Yoosuf AA, Nazeem A, Latheef AA. Coronavirus disease 2019 and dengue: two case reports. J Med Case Rep. 2021 Mar 26;15(1):171. doi:10.1186/s13256-021-02707-7.
- Joob B, Wiwanitkit V. Letter to the editor: Coronavirus disease 2019 (COVID-19), infectivity, and the incubation period. J Prev Med Public Health. 2020 Mar;53(2):70. doi:10.3961/jpmph.20.065.
- Čiučiulkaitė I, Möhlendick B, Thümmler L, Fisenkci N, Elsner C, Dittmer U, Siffert W, Lindemann M. GNB3 c.825c>t polymorphism influences T-cell but not antibody response following vaccination with the mRNA-1273 vaccine. Front Genet. 2022 Aug 29;13:932043. doi:10.3389/fgene.2022.932043.